Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Clinical trials sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., explained in plain language.
A pharmaceutical R&D subsidiary of Sino Biopharmaceutical, focusing on drug development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase: PHASE1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New antibody injection takes aim at Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis study tests a new drug called TQB2922, given as a shot under the skin, for people with head and neck cancer that has come back or spread. The drug is a special antibody that targets two proteins (EGFR and c-Met) involved in cancer growth. The trial has two parts: first, find…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to outsmart recurrent lymphoma
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned …
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC